%0 Journal Article
%T Therapeutic concentrations of glucagon-like peptide-1 in cerebrospinal fluid following cell-based delivery into the cerebral ventricles of cats
%A Silke Glage
%A Petra M Klinge
%A Miles C Miller
%A Christine Wallrapp
%A Peter Geigle
%A Hans J Hedrich
%A Thomas Brinker
%J Fluids and Barriers of the CNS
%D 2011
%I BioMed Central
%R 10.1186/2045-8118-8-18
%X Cells were packed in a water-permeable mesh bag containing 400 polymeric microcapsules, each containing 3000 cells. The mesh bags were either transplanted into the subdural space, into the brain parenchyma or into the cerebral ventricles of the cat brain. Mesh bags were explanted after two weeks, and cell viability, as well as GLP-1 concentration in the cerebrospinal fluid (CSF), was measured.Viability of cells did not significantly differ between the three implantation sites. However, CSF concentration of GLP-1 was significantly elevated only after ventricular transplantation with a maximum concentration of 73 pM (binding constant = 70 pM).This study showed that ventricular cell-based delivery of soluble factors has the capability to achieve concentrations in the CSF which may become pharmacologically active. Despite the controversy about the pharmacokinetic limitations of ventricular drug delivery, there might be a niche in this for encapsulated cell biodelivery of soluble, highly biologically-effective neuropeptides of low molecular weight like GLP-1.Neurotrophic peptides may have considerable potential in the treatment of acute and chronic neurological diseases. However, systemic delivery is limited by significant systemic side effects, short plasma half-life or poor blood-brain barrier passage. Therefore, local administration into the central nervous system (CNS) has been proposed [1,2]. However, this drug delivery route, bypassing the blood brain barrier, has been challenged, because substances are rapidly removed from the brain through physiological cerebrospinal fluid (CSF) outflow pathways [3-5].Ex vivo gene therapy using encapsulated cell biodelivery has been suggested as a way to achieve a more sustained local delivery of proteins into the CNS. Bankable, non-autologous cell lines cells can be used, that have been genetically engineered to produce the protein. To prevent host versus graft reaction, encapsulation of those cells with permselective membranes
%U http://www.fluidsbarrierscns.com/content/8/1/18